Low dose zolmitriptan as a 5-HT neuroendocrine challenge agent in humans

F. Gerard Moeller, James M. Bjork, Donald M Dougherty, Louis D. Van De Kar, Dawn M. Marsh, Alan C. Swann

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

The 5-HT1B/D agonist sumatriptan has been used in a number of studies as a neuroendocrine challenge agent. Whether its neuroendocrine effects are centrally mediated is unclear, however, since sumatriptan shows minimal penetration of the central nervous system. Zolmitriptan shows a greater penetration into the central nervous system than sumatriptan, and has recently been shown to be an effective challenge agent. In order to determine the neuroendocrine, temperature and side effects of a 2.5 mg oral dose of zolmitriptan, 17 healthy volunteers underwent a placebo controlled, repeated measures, double blind neuroendocrine challenge. Zolmitriptan or placebo were administered, and cortisol, growth hormone, prolactin, blood pressure and temperature, were measured over four hours after the dose of zolmitriptan. Zolmitriptan at this dose was well tolerated by all subjects, with minimal side effects and only minor effects on blood pressure. There was a significant increase in serum growth hormone after zolmitriptan compared to placebo, however there were no significant effects on cortisol, prolactin or oral temperature. The neuroendocrine effects of 2.5 mg of orally administered zolmitriptan are similar to previously reported effects of sumatriptan, with minimal side effects. Copyright (C) 2000 Elsevier Science Ltd.

Original languageEnglish (US)
Pages (from-to)607-618
Number of pages12
JournalPsychoneuroendocrinology
Volume25
Issue number6
DOIs
StatePublished - Aug 2000
Externally publishedYes

Fingerprint

zolmitriptan
Serotonin
Sumatriptan
Placebos
Prolactin
Growth Hormone
Temperature
Hydrocortisone
Central Nervous System
Blood Pressure
Serotonin 5-HT1 Receptor Agonists

Keywords

  • Cortisol
  • Growth hormone
  • Neuroendocrine challenge
  • Prolactin
  • Serotonin
  • Zolmitriptan

ASJC Scopus subject areas

  • Endocrinology
  • Endocrinology, Diabetes and Metabolism
  • Psychiatry and Mental health
  • Biological Psychiatry
  • Endocrine and Autonomic Systems
  • Psychology(all)

Cite this

Moeller, F. G., Bjork, J. M., Dougherty, D. M., Van De Kar, L. D., Marsh, D. M., & Swann, A. C. (2000). Low dose zolmitriptan as a 5-HT neuroendocrine challenge agent in humans. Psychoneuroendocrinology, 25(6), 607-618. https://doi.org/10.1016/S0306-4530(00)00013-5

Low dose zolmitriptan as a 5-HT neuroendocrine challenge agent in humans. / Moeller, F. Gerard; Bjork, James M.; Dougherty, Donald M; Van De Kar, Louis D.; Marsh, Dawn M.; Swann, Alan C.

In: Psychoneuroendocrinology, Vol. 25, No. 6, 08.2000, p. 607-618.

Research output: Contribution to journalArticle

Moeller, F. Gerard ; Bjork, James M. ; Dougherty, Donald M ; Van De Kar, Louis D. ; Marsh, Dawn M. ; Swann, Alan C. / Low dose zolmitriptan as a 5-HT neuroendocrine challenge agent in humans. In: Psychoneuroendocrinology. 2000 ; Vol. 25, No. 6. pp. 607-618.
@article{5b1ed14870754e9f8d7140553afc2d85,
title = "Low dose zolmitriptan as a 5-HT neuroendocrine challenge agent in humans",
abstract = "The 5-HT1B/D agonist sumatriptan has been used in a number of studies as a neuroendocrine challenge agent. Whether its neuroendocrine effects are centrally mediated is unclear, however, since sumatriptan shows minimal penetration of the central nervous system. Zolmitriptan shows a greater penetration into the central nervous system than sumatriptan, and has recently been shown to be an effective challenge agent. In order to determine the neuroendocrine, temperature and side effects of a 2.5 mg oral dose of zolmitriptan, 17 healthy volunteers underwent a placebo controlled, repeated measures, double blind neuroendocrine challenge. Zolmitriptan or placebo were administered, and cortisol, growth hormone, prolactin, blood pressure and temperature, were measured over four hours after the dose of zolmitriptan. Zolmitriptan at this dose was well tolerated by all subjects, with minimal side effects and only minor effects on blood pressure. There was a significant increase in serum growth hormone after zolmitriptan compared to placebo, however there were no significant effects on cortisol, prolactin or oral temperature. The neuroendocrine effects of 2.5 mg of orally administered zolmitriptan are similar to previously reported effects of sumatriptan, with minimal side effects. Copyright (C) 2000 Elsevier Science Ltd.",
keywords = "Cortisol, Growth hormone, Neuroendocrine challenge, Prolactin, Serotonin, Zolmitriptan",
author = "Moeller, {F. Gerard} and Bjork, {James M.} and Dougherty, {Donald M} and {Van De Kar}, {Louis D.} and Marsh, {Dawn M.} and Swann, {Alan C.}",
year = "2000",
month = "8",
doi = "10.1016/S0306-4530(00)00013-5",
language = "English (US)",
volume = "25",
pages = "607--618",
journal = "Psychoneuroendocrinology",
issn = "0306-4530",
publisher = "Elsevier Limited",
number = "6",

}

TY - JOUR

T1 - Low dose zolmitriptan as a 5-HT neuroendocrine challenge agent in humans

AU - Moeller, F. Gerard

AU - Bjork, James M.

AU - Dougherty, Donald M

AU - Van De Kar, Louis D.

AU - Marsh, Dawn M.

AU - Swann, Alan C.

PY - 2000/8

Y1 - 2000/8

N2 - The 5-HT1B/D agonist sumatriptan has been used in a number of studies as a neuroendocrine challenge agent. Whether its neuroendocrine effects are centrally mediated is unclear, however, since sumatriptan shows minimal penetration of the central nervous system. Zolmitriptan shows a greater penetration into the central nervous system than sumatriptan, and has recently been shown to be an effective challenge agent. In order to determine the neuroendocrine, temperature and side effects of a 2.5 mg oral dose of zolmitriptan, 17 healthy volunteers underwent a placebo controlled, repeated measures, double blind neuroendocrine challenge. Zolmitriptan or placebo were administered, and cortisol, growth hormone, prolactin, blood pressure and temperature, were measured over four hours after the dose of zolmitriptan. Zolmitriptan at this dose was well tolerated by all subjects, with minimal side effects and only minor effects on blood pressure. There was a significant increase in serum growth hormone after zolmitriptan compared to placebo, however there were no significant effects on cortisol, prolactin or oral temperature. The neuroendocrine effects of 2.5 mg of orally administered zolmitriptan are similar to previously reported effects of sumatriptan, with minimal side effects. Copyright (C) 2000 Elsevier Science Ltd.

AB - The 5-HT1B/D agonist sumatriptan has been used in a number of studies as a neuroendocrine challenge agent. Whether its neuroendocrine effects are centrally mediated is unclear, however, since sumatriptan shows minimal penetration of the central nervous system. Zolmitriptan shows a greater penetration into the central nervous system than sumatriptan, and has recently been shown to be an effective challenge agent. In order to determine the neuroendocrine, temperature and side effects of a 2.5 mg oral dose of zolmitriptan, 17 healthy volunteers underwent a placebo controlled, repeated measures, double blind neuroendocrine challenge. Zolmitriptan or placebo were administered, and cortisol, growth hormone, prolactin, blood pressure and temperature, were measured over four hours after the dose of zolmitriptan. Zolmitriptan at this dose was well tolerated by all subjects, with minimal side effects and only minor effects on blood pressure. There was a significant increase in serum growth hormone after zolmitriptan compared to placebo, however there were no significant effects on cortisol, prolactin or oral temperature. The neuroendocrine effects of 2.5 mg of orally administered zolmitriptan are similar to previously reported effects of sumatriptan, with minimal side effects. Copyright (C) 2000 Elsevier Science Ltd.

KW - Cortisol

KW - Growth hormone

KW - Neuroendocrine challenge

KW - Prolactin

KW - Serotonin

KW - Zolmitriptan

UR - http://www.scopus.com/inward/record.url?scp=0034096291&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034096291&partnerID=8YFLogxK

U2 - 10.1016/S0306-4530(00)00013-5

DO - 10.1016/S0306-4530(00)00013-5

M3 - Article

C2 - 10840172

AN - SCOPUS:0034096291

VL - 25

SP - 607

EP - 618

JO - Psychoneuroendocrinology

JF - Psychoneuroendocrinology

SN - 0306-4530

IS - 6

ER -